TOPICALLY & TRANSDERMALLY STUDIED PEPTIDES / MATRIX
Three Peptides, Three Ways In
How a copper tripeptide, a GLP-1 analogue, and a thymic peptide differ in mechanism, delivery route, evidence maturity, and what each is actually studied for.
The short version
This page lines up GHK-Cu, semaglutide, and thymosin alpha-1 on the dimensions that matter most for understanding research peptides as a category: what each one is for, how it is actually delivered into or onto the body, how strong its evidence is, and its regulatory standing. The headline is simple. All three are peptides — short chains of amino acids — but they occupy almost entirely different scientific worlds: a cosmetic-adjacent copper carrier studied on the skin's surface, an FDA-approved metabolic drug studied by injection and, with real engineering effort, by mouth, and a thymic immune signal studied exclusively by injection with a genuinely mixed trial record. None of this is medical advice, and no human dose is recommended anywhere on this page.
The comparison matrix
| Dimension | GHK-Cu | Semaglutide | Thymosin Alpha-1 |
|---|---|---|---|
| Peptide class | Copper-binding tripeptide (cosmetic ingredient / research peptide) | GLP-1 receptor agonist (incretin mimetic) | Thymic immunomodulatory peptide |
| Studied delivery route | Topical / transdermal, directly measured skin permeation [5] | Subcutaneous injection (approved); oral tablet with absorption enhancer, ~0.4-1% bioavailability [12] | Subcutaneous injection only |
| Most-studied in | Skin aging, wound healing, hair growth | Type 2 diabetes, obesity, cardiovascular and kidney outcomes | Sepsis, chronic viral hepatitis, cancer immunotherapy adjuvant |
| Evidence base | Small human topical/hair trials plus extensive in vitro and gene-expression work [1][3][4] | Large multi-thousand-participant RCTs (STEP, SELECT, FLOW) [9][10][11] | Mixed: decades of small-to-moderate trials plus one large null phase 3 trial [13][17] |
| Regulatory status | Legal cosmetic ingredient; no approved drug product for any route | FDA-approved (multiple indications) | Approved (thymalfasin) in 35+ countries; not FDA-approved in the US |
| Key caution | Formulation stability with vitamin C/acids; limited human evidence at scale | GI intolerance; weight regain after stopping | Efficacy expectations tempered by the 2025 null sepsis trial [13] |
Peptide class and mechanism
The three compounds could hardly be more structurally different. GHK-Cu is a three-amino-acid tripeptide chelated to a single copper ion, acting locally wherever it is applied or retained. Semaglutide is a 31-amino-acid analogue of a human gut hormone, chemically modified with a fatty-acid side chain so it can circulate in the bloodstream for about a week and act on receptors in the pancreas, gut, and brain. Thymosin alpha-1 is a 28-amino-acid immune-signaling peptide that works through pattern-recognition receptors on dendritic cells and monocytes, shaping the broader immune response rather than acting on any single organ.
That structural range is not incidental to the delivery question. GHK-Cu's small size and specific chemistry are part of why its skin-crossing behavior has actually been measured [5]; semaglutide's size and receptor targets meant delivery engineering had to solve a blood-circulation problem instead [12]; thymosin alpha-1's role as a systemic immune signal never made a topical route relevant to begin with.
Studied delivery route
This is the dimension that organizes the whole desk. GHK-Cu is the outlier: a human skin-penetration study measured the intact tripeptide crossing dermatomed skin at a defined rate, with a meaningful fraction retained in the dermis as a depot [5] — a rare, directly quantified transdermal story most peptides never generate. Semaglutide's studied routes are a once-weekly subcutaneous injection, its primary and most-studied form, and a once-daily oral tablet that required co-formulating the peptide with an absorption enhancer just to reach roughly 0.4-1% bioavailability [12]. Thymosin alpha-1 has no topical or oral formulation in the published record at all — every trial establishing its dosing and safety profile used subcutaneous injection [14].
Put simply: one peptide's evidence base is built around the skin, one is built around a heavily engineered path into the blood, and one never left the injection needle.
Evidence base
The three separate sharply here. Semaglutide has the deepest and most diverse clinical record: multi-thousand-participant randomized trials spanning weight management, cardiovascular outcomes, and kidney disease, plus years of pharmacovigilance data [9][10][11][12]. GHK-Cu's record is a mix of small controlled human topical and hair trials, extensive in vitro fibroblast work, and broader gene-expression database analyses that this desk treats as suggestive rather than confirmed [1][2][3][7]. Thymosin alpha-1's record is the most genuinely mixed of the three: decades of small-to-moderate trials showing encouraging signals in sepsis, hepatitis, and cancer contexts, capped by a large, rigorous 2025 phase 3 trial that found no mortality benefit in sepsis at all [13][17]. Reading the trajectory of each honestly, rather than picking the single most favorable study, is the whole point of putting them side by side.
Regulatory status
Semaglutide is an FDA-approved prescription medicine across several indications. GHK-Cu, as Copper Tripeptide-1, is a legal cosmetic ingredient in the US, EU, and UK — but there is no FDA- or EMA-approved drug product containing it for any indication, and injectable or systemic use is unapproved and research-only. Thymosin alpha-1 (thymalfasin) is approved as a drug in more than 35 countries but has no US marketing approval; American access is limited to investigational and compounding contexts [14]. None of the three should be understood as interchangeable in regulatory standing — one is a widely sold cosmetic ingredient, one is an approved pharmaceutical, and one is approved abroad but not domestically.
Key caution
Each compound carries a defining caveat. For GHK-Cu, it is the combination of genuinely limited human evidence at scale and a formulation-stability issue — combining it with vitamin C or strong acids can break apart the copper-peptide complex [1]. For semaglutide, it is gastrointestinal intolerance during dose escalation paired with the well-documented pattern of weight regain once the drug is stopped, framing it as chronic rather than curative therapy [12]. For thymosin alpha-1, it is the tension between decades of encouraging smaller studies and the largest, most rigorous trial to date coming back null [13] — a caution against assuming benefit beyond the settings where the evidence is genuinely strongest. Read together, the pattern is instructive: more scale and rigor in a trial program does not always confirm the smaller studies that came before it.